BACKGROUND
Although cancer and acute myocardial infarction (MI) often coexist, the prognostic impact of revascularization for MI in patients with cancer remains unclear.
OBJECTIVES
The authors aim to evaluate the incidence of MI among patients with cancer and the prognostic impact of revascularization for MI in patie...
Seung-Hun Lee, Dong Hyun Gim, D. Kang et al.· JACC: Asia· 1 citation
Background:
Current guidelines recommend that very-high-risk patients with diabetes after acute myocardial infarction (AMI) achieve both an absolute low-density lipoprotein cholesterol (LDL-C) goal of <55 mg/dL and a reduction of ≥50% from baseline. However, in routine practice, many patients fail to achieve both ta...
J. Lee, Yoonsun Won, A. Jang et al.· Circulation· 0 citations
BACKGROUND
The role of fractional flow reserve (FFR)-guided revascularisation in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) is unclear.
AIMS
We sought to compare the outcomes of FFR-guided and angiography-guided revascularisation in patients with NSTE-ACS and chronic coronary syndrome...
L. Paolucci, B. de Bruyne, G. Rioufol et al.· EuroIntervention· 0 citations
In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction defined by MRR ≤2.5 was observed among one-third of patients, and was associated with an increased risk of a composite of all-cause death, myocardial infarction, clinically-driven repeat revas...
Seung-Hun Lee, J. Ahn, W. Jones et al.· European Heart Journal· 0 citations
In patients with remote PCI and a high risk of recurrent ischaemic events, clopidogrel monotherapy showed a directionally consistent reduction in the composite endpoint of all-cause death, myocardial infarction, or stroke compared with aspirin in both females and males, supporting the consistency of the treatment effec...
Woo-Duk Kwon, Ki H. Choi, Yonghwan Park et al.· EuroIntervention· 0 citations
In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints.
J. Silvain, Ki H. Choi, Victorien Monguillon et al.· The Lancet· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.